At CureSearch for Children's Cancer, we’re dedicated to ensuring that every child diagnosed with cancer has a safe and effective treatment option. We only fund translational research projects with the strongest potential to become a new treatment and quickly reach patients.

**Mission:** It is our mission to end childhood cancer by driving targeted and innovative research with measurable results in an accelerated time frame.

**Impact:** It is our goal to protect the future of children diagnosed with cancer. We’re not only demonstrating an incredible success rate in driving projects into clinical trials, but we're also doing it at a faster pace. Read about our impact.
Video: Who is CureSearch? Leaders from across pediatric cancer explain the urgent, critical need for new childhood cancer treatments, and how CureSearch is changing the odds for the 42 children diagnosed each day.
We only fund translational research projects with the strongest potential of becoming new treatments and reaching patients quickly.

- Of those projects funded through our Acceleration Initiative, an average 60% advance to preclinical trials. This is compared to a national average rate of translation of less than 8%.

- Those projects are 7x more likely to advance to clinical trials and get there 1.5x faster compared to the national average.

- Our success is measured by the rate of a funded project’s progress toward the clinic and marketplace where new treatments can directly impact patients, not by total dollars spent or by publishing in academic journals.

- Leveraging our unique position and extensive relationships, we convene leaders from all areas of the global pediatric cancer ecosystem — academia, regulatory, pharma, funding organizations, partners, donors and volunteers — to drive the collaborations necessary to accelerate the pace of pediatric cancer research.

- Our stakeholder meetings directly influence and advance pediatric cancer research and drug development.
Drug development for pediatric cancers with insufficient or ineffective treatment options is critical, and is a central focus of our research strategy. Our unique funding strategy focuses on addressing areas of unmet need in childhood cancer including:

- Cancers with the lowest survival rates
- Cancers with limited or most damaging treatment options
- Populations that are underserved, including adolescents and young adults

At CureSearch, we support eligible researchers from diverse backgrounds – including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social, and clinical sciences – and addressing the urgent need for new pediatric cancer treatments for cancers with the lowest survival rates, limited treatment options, and for populations that are underserved.
Our research programs are focused on saving children, faster. Our three distinct research programs fund both pre-clinical and clinical research, and are each designed to accelerate the pace of pediatric drug development and deliver new treatments directly to the children who so desperately need them:

- **Young Investigator** – Young Investigator Awards combat the loss of promising scientists from the field by providing significant financial support to investigators early in their research careers.

- **Acceleration Initiative** – Acceleration Initiative projects are highly innovative, address a significant challenge in pediatric cancer drug development, and have a strong probability of clinical application.

- **Catapult Awards** – Catapult Awards provide funding for Phase 1 or Phase 2 clinical trials that advance promising therapies for pediatric cancer.
Of the limited general funding that exists, it typically will only support basic or discovery phase research. On the opposite end of the development timeline, late-phase clinical trials are supported by biotech and pharmaceutical companies.

There is a significant funding gap for those areas in between, where translational, preclinical, and early-phase clinical trials lie. This focus on translational research – bench to bedside – is critical.

CureSearch’s funding efforts aim to fill that gap and ensure that promising new therapies make it into clinical trials.
CureSearch Research Programs Bridge the Translation Gap

Basic Research → Drug Discovery & Design → Preclinical Development → Early Phase Clinical Trials → Late Phase Clinical Trials → FDA Application & Approved

Translational Research Funding Gap

Federal Funding → Pharma Funding
CureSearch collaborates with key players in pediatric oncology drug development to evaluate proposed research projects for scientific merit, clinical feasibility and commercialization potential.

**Scientific Advisory Council** – The Scientific Advisory Council (SAC) includes best-in-class pediatric oncologists who set the academic priorities for CureSearch research initiatives and evaluate projects on scientific merit.

**Industry Advisory Council** – The Industry Advisory Council (IAC) includes leaders from the largest global oncology and biotechnology companies who review potential projects for clinical, commercial and regulatory feasibility and provides objective counsel to assess clinical translation and drug development potential.
OUR RESEARCH EVENTS

The CureSearch Summit and Pediatric Early Development Symposium bring together key stakeholders to directly influence and advance pediatric cancer research and drug development.

**CureSearch Summit** – The annual CureSearch Summit creates connections and community among leaders in science, academia, regulatory, funding and industry by providing platforms for engagement. These critical conversations help drive innovation.

**Pediatric Early Development Symposium (PEDS)** – PEDS Launched in 2020 in response to the passage of Title V of the FDA Reauthorization Act, commonly known as the RACE for Children Act, the CureSearch Pediatric Early Development Symposium (PEDS) serves as an opportunity for industry, academia and regulatory leaders to examine the dynamic nature of clinical trials for a super rare population - children with cancer.
Together, we create connections and community to quickly drive cutting-edge research that will bring safe, effective treatment options to the kids who are counting on us. Our nationwide fundraising events bring communities together in support of our shared mission to end childhood cancer.

• **The CureSearch Ultimate Hike** is a life-changing, lifesaving adventure that gives you the opportunity to tell children’s cancer to “take a hike” by trekking 20-30 miles in one day.

• **CureSearch Gold** is a fun way to use your DIY skills to create an awesome fundraising opportunity in your own community.

• **CureSearch Walks** bring together families, friends and community members who raise funds, and honor and remember those affected by cancer.
EDUCATIONAL RESOURCES

CureSearch has a variety of resources to help families navigate a cancer diagnosis.

• **Clinical Trial Finder** – Our clinical trial finder offers a simple way to identify clinical trials in any location that may benefit both current patients and the entire pediatric cancer community.

• **Educational Resources** – Our website has free resources including a clinical trial finder and educational videos to help patients and families better understand childhood cancer.

• **Brave Barbie®** – Through a partnership with Mattel, we provide kids affected by cancer with a special brave Barbie. These bald dolls are a great way to help children better understand hair loss associated with treatment.
CHILDHOOD CANCER STATS

- Cancer is the #1 cause of death by disease in children.
- More than 15,000 children are diagnosed with cancer in the US every year.
- 42 children are diagnosed every day.
- Despite progress in treating the most common forms of childhood cancer, survival rates for many other types of childhood cancer remain dismal.
- For many high-risk subtypes, long-term survival rates are often less than 50%. And some, such as DIPG, remain universally fatal.
- Due to toxic treatments, 2 out of 3 childhood cancer survivors will develop at least one chronic health condition, including musculoskeletal problems and secondary cancers.
- Nearly 60% of childhood cancer survivors experience severe complications in adulthood.
- Most standard childhood cancer treatments were approved before 1990; half before the mid-1980's.
“While funding exists for new discoveries, little to no funding infrastructure is in place for catalysis and development of these discoveries into first-in-human clinical trials. This is often referred to as the ‘valley of death.’ CureSearch exists to fill this valley.” - Elias Sayour, MD, PhD, Catapult Award Recipient

"I cannot think of any other pediatric cancer foundation that operates at the level of CureSearch. Their research strategy will benefit children by getting new therapies faster into the clinic." - Dr. Ranjit Bindra, MD, PhD of Yale University, Catapult Award Recipient
For media inquiries, contact:
Margetta Thomas, Communications Manager
margetta.thomas@curesearch.org
(240) 235-2283